Healthcare & Pharmaceutical Awards 2019

GHP / 2019 Healthcare & Pharmaceutical Awards 17 g Neuro-Sys: Thanks to the expertise of its team and its commitment to excellence, Neuro-Sys has become over the years the preferred partner of the pharmaceutical industry and biotech- nology companies internationally that carry out pre-clinical trials dedicated to Alzheimer’s, Parkinson’s, Charcot’s and Huntington’s diseases. Moreover, the company has estab- lished strong worldwide strategic partnerships with the pharmaceutical industry and bio- technology companies. With such a dedicated team, the company successfully offers a global service including drug development consulting up to the clinical stage. As a result, Neuro-Sys has established itself as a worldwide expert for the development of compounds in the field of neurodegenerative diseases. The firm’s expert team implements significant continuous R&D that ensures models to be more efficient and always ahead of the competition. As part of this focus on continuous improvement, Neuro-Sys is also very close to its customers with a collaborative approach, whether on a technical, scientific or strategic level. Therefore, the firm is able to remain ahead of emerging industry developments and offers patients and healthcare professionals the solutions they need. The firm holds a scientific board on a monthly basis with leading scientists to support the development of its scientific expertise so that it is constantly ahead of emerging market developments. Dedicated to giving back to the healthcare industry and supporting professionals throughout, Neuro-Sys publishes scientific articles and regularly presents the results of its research on the international pharmacological scene during conferences and congresses. In 2018, it presented no less than eight scientific posters at seven events. This ongoing research makes it possible to optimize existing models and develop new ones, but also to understand each other’s mechanisms in order to better drive the devel- opment of new molecules. Recently, in order to build upon its already impressive success, Neuro-Sys, in association with Gain Therapeutics and the Institute for Research in Biomedicine were awarded a € 1.4M grant support from Eurostars-2, after having scored 2nd among 325 eligible applications. This grant will further strengthen a novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the treatment of Gaucher Disease, GM1 Gangliosidosis and Parkinson’s Disease. Such a development will help Neuro-Sys to grow and flourish over the coming years, and this is its primary goal. With this in mind, Neuro-Sys has just opened its American branch in Boston, MA to respond more effectively to its customers. The firm has also doubled its automatic test capacity ( 500 m² ) and increased its R&D department to support this growth and ensure that its quality and innovation remains unchanged. Ultimately, with 11 scientists out of 14 employees and up to 20 years of experience in the field of neuroscience and pharmaceutical development, few CROs are able to provide such a high level of scientific expertise as Neuro-Sys can, and as such clients know that they are in safe hands when they work with this dynamic company and use its innovative solutions. Supporting even more healthcare professionals and patients will remain Neuro- Sys core focus as it grows into new territories and markets. Name: Dr Noelle Callizot Address: 410 Chemin Départemental 600 - 13120 Gardanne - France Telephone Number: +33413415171 Web Address: www.neuro-sys.com